Market news
EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ('BioAge', 'the Company'), a clinical-stage biotechnolog...
Detailed price information for Freeport-Mcmoran Inc (FCX-N) from The Globe and Mail including charting and trades.
Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapyPrimary...
BioAge's diversified pipeline includes ophthalmology and apelin-APJ pathway programs, and partnerships with Novartis and Eli Lilly. See why BIOA stock is a buy.
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ('BioAge', 'the Company'), a clinical-stage biotechnolog...
Detailed price information for Fiserv Inc (FISV-Q) from The Globe and Mail including charting and trades.
Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.
BioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of +10.77% and +172.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026 QUELL-DME, Phase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema, planned to initiate in mid-2026, with data anticipated in mid-2027; results expected to support development across inflammation-driven retinal diseases Hosted R&D Day focused on NLRP3 inhibition, featuring Phase 1 d
BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.
This is the newest page. Registered accounts read further back.